JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

Inclusion Criteria: * Histologically (or cytologically) confirmed, unresectable metastatic colorectal cancer. * KRAS G12C mutation. * At least one measurable disease per RECIST v1.1; assessed within 28 days before first dose. * Subject have withdrawn from the first-line chemotherapy due to disease progression or unacceptable toxicity; if first-line chemotherapy and maintenance therapy were received, disease progression must within three months; first-line chemotherapy regimens do not limit the use of antiangiogenic agents. * Adequate bone marrow, liver and renal function. * ECOG performance status 0-1. * Informed consent has been signed. Exclusion Criteria: * Patients have received KRAS G12C inhibitors. * Patients have received a first-line treatment, which include fluoropyrimidine, oxaliplatin and irinotecan. * Patients who are pregnant or breastfeeding. * Life expectancy of less than 3 months. * Patients who had major surgery or significant trauma within 4 weeks prior to the first blood sample collection during the screening period, or expected to require major surgery during the study period. * Patients with active ulcers and gastrointestinal bleeding. * Prior history of interstitial lung disease or non-infectious pneumonia; history of active tuberculosis. * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. * Patients with clinically diagnosed autoimmune disease; HIV, HCV positive; HBV-DNA beyond the normal range of the laboratory; Acute CMV infection. * Patients with active central nervous system metastases requiring treatment. * Patients with other malignancies within five years. * Assessed by the investigator, patients who are unable or unwilling to comply with the requirements of the study protocol.